• About us
• Contact

Advertisement

Organisation › Details

Novo Holdings A/S

Novo Holdings is a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes (the Novo Group companies) and manages an investment portfolio with a long-term return perspective. The investment portfolio comprises two teams including Life Science Investments and Capital Investments. The Life Science Investments team invests in companies at all stages of development and includes Seed Investments, Venture Investments, Growth Investments and Principal Investments. The Capital Investments team manages a broad portfolio of equities, bonds, real estate and infrastructure assets, as well as private equity investments. Novo Holdings operates out of offices in Copenhagen, London, Boston, San Francisco, Singapore and Shanghai. As of year-end 2021, Novo Holdings had total assets of USD 106 billion. *

 

	Start	2017-06-23 renamed
	Group	Novo Group (Group)
	Industry	venture capital
	Street	19 Tuborg Havnevej
	City	2900 Hellerup
	Tel	+45-3527-6500
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	106,000,000,000 (assets (2023) 2023-04-13)
		* Document for »About Section«: Alentis Therapeutics AG. (4/13/23). "Press Release: Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1". Basel.
		Record changed: 2024-02-12

Advertisement

More documents for Novo Group (Group)

• [1] CMS Hasche Sigle. (3/26/24). "Press Release: CMS Advises Sellers of Cardior Pharmaceuticals on Potential Acquisition by Novo Nordisk". Munich....
• [2] Cardior Pharmaceuticals GmbH. (3/25/24). "Press Release: Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease". Bagsværd & Hannover....
• [3] LimmaTech Biologics AG. (10/9/23). "Press Release: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections". Schlieren....
• [4] Bactolife A/S. (8/8/23). "Press Release: Bactolife Raises EUR 30 Million in Series A Financing". Copenhagen....
• [5] BioGeneration Ventures B.V.. (7/13/23). "Press Release: BioGeneration Ventures Closes BGV Fund V at €150 Million". Naarden....
• [6] Engimmune Therapeutics AG. (5/3/22). "Press Release: Engimmune Therapeutics Raises CHF 15.5 Million in Seed Financing to Develop Novel T-cell Receptor Therapeutics". Basel....
• [7] Novo Nordisk Foundation. (9/22/21). "Press Release: New Research Center Will Find Solutions to Reduce CO2 in the Atmosphere and Convert it into Valuable Raw Materials"....
• [8] Forbion Capital Partners. (9/1/21). "Press Release: Forbion Appoints Nanna Lüneborg as a General Partner". Naarden....
• [9] Cardior Pharmaceuticals GmbH. (8/25/21). "Press Release: Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease". Hanover....
• [10] Numab Therapeutics AG. (5/20/21). "Press Release: Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing". Wädenswil (Zurich)....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.